Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma

Status No longer available

Clinical Trial Summary

A multicenter, open-label expanded access program to provide access to tazemetostat to Epithelioid Sarcoma (ES) patients in serious need who are otherwise unable to participate in a clinical study or whom access is not available through marketed product in the US.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04225429
Study type	Expanded Access
Source	Ipsen
Contact
Status	No longer available
Phase

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05415098` - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas	Phase 1
Recruiting	`NCT05286801` - Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	Phase 1/Phase 2
Completed	`NCT00464620` - Trial of Dasatinib in Advanced Sarcomas	Phase 2
Active, not recruiting	`NCT03069378` - A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma	Phase 2
Completed	`NCT03837678` - Epithelioid Sarcoma Natural History Study
Active, not recruiting	`NCT02180867` - Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery	Phase 2/Phase 3
Recruiting	`NCT04008238` - Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients	N/A
Completed	`NCT02584309` - Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma	Phase 2
Not yet recruiting	`NCT06277154` - MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma	Phase 2
Completed	`NCT02601950` - A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma	Phase 2
Completed	`NCT03190174` - Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers	Phase 1/Phase 2
Recruiting	`NCT03099681` - An Observational Study on Epithelioid Sarcoma
Recruiting	`NCT04416568` - Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers	Phase 2
Recruiting	`NCT05407441` - Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors	Phase 1/Phase 2
Recruiting	`NCT03967834` - Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group	N/A